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Abstract
Background: Mild hypothermia (34–35 °C) increases perioperative blood loss. Our previous studies showed that
desmopressin could have in vitro beneficial effects on hypothermia-induced primary haemostasis impairment. In this
study, we investigate the in vitro effects of desmopressin on hypothermia-induced primary haemostasis impairment
under the influence of aspirin in healthy volunteers.
Methods: Sixty healthy volunteers were randomly allocated to taking aspirin 100 mg or placebo for three days. On
the sixth day blood samples were taken before and after the injection of desmopressin (1.5 microgram or 5
microgram) or normal saline subcutaneously. Measurements including Platelet Function Analyzer (PFA-100®) closure
times, plasma von Willebrand Factor antigen, haemoglobin and platelet levels were made at 32 °C and 37 °C
respectively.
Results: Collagen/epinephrine closure time (EPICT) was significantly prolonged by 21.13 % (95 %CI 2.34–39.74 %,
p = 0.021) in aspirin group at 37 °C. While hypothermia alone prolonged both collagen/adenosine diphosphate
(ADPCT) and EPICT by 17.63 % (95 %CI 13.5–20.85 %, p < 0.001) and 8.0 % (95 %CI 6.38–10.04 %, p = 0.024)
respectively, addition of aspirin only further prolonged EPICT by 19.9 % (95 %CI 3.32–36.49 %, p = 0.013). In aspirin
group, desmopressin 1.5 microgram and 5 microgram significantly reduced ADPCT to below baseline levels at 37 °C
(p = 0.025 and <0.001 respectively), whereas reduction in EPICT was seen with desmopressin 5 microgram (p =0.008).
The effect was less pronounced at 32 °C, with a significant reduction in EPICT obtained with a dosage of 5 microgram
only (p = 0.011).
Conclusion: It was shown that aspirin could further potentiate the hypothermia-induced closure time prolongations.
Low dose desmopressin (1.5 microgram) reduced PFA-100® closure times towards baseline. A higher dosage
(5 microgram) further reduced the closure times below baseline. Therefore low dose desmopressin (1.5 microgram)
might have the potential to correct hypothermia-induced primary haemostasis impairment under the influence of
aspirin during the perioperative period.
Trial registration: ClinicalTrials.gov: NCT01382134
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Background
Aspirin is the most commonly taken anti-platelet drug.
While it has roles in primary and secondary preventions
in a variety of thromboembolic conditions, it can also
lead to impairment in primary haemostasis. In particular,
pre-operative aspirin intake has been associated with in-
creased post-operative blood loss [1–3]. In the recent
POISE-2 study, it was shown that peri-operative intake
of aspirin (100-200 mg daily) increased risk of major
bleeding in patients, while risk of death or non-fatal
myocardial infarction was not reduced when compared
to the placebo group [4]. There is always a dilemma on
whether cessation of anti-platelet therapy during the
peri-operative period would increase the risk of throm-
boembolic event, especially in patients with increased
cardiovascular risks [5, 6]. Given the widespread use of
aspirin in primary and secondary cardiovascular disease
preventions, it is not uncommon that patients will be
under its influence during the peri-operative period. On
the other hand, intra-operative hypothermia may also
have a negative impact on perioperative blood loss as
well. It was previously shown that hypothermia (34–35 °C)
increased surgical bleeding and transfusion requirements
in both cardiac and non-cardiac surgery [7–10]. Hypo-
thermia also plays a significant role in coagulopathy in
trauma patients and those requiring massive transfusion
[11, 12]. While hypothermia might be difficult to avoid to-
tally, it was found that low dose desmopressin might have
beneficial effect on the primary haemostasis impairment it
causes [13, 14]. We therefore conducted this study to
evaluate any effect of aspirin on hypothermia-induced pri-
mary haemostasis impairment, and whether low dose des-
mopressin could possibly influence such effect.
Methods
The study was approved by the Hong Kong West Cluster/
University of Hong Kong Institutional Review Board
(Reference number: UW11-075) and registered at
www.ClinicalTrials.gov with Trial Registration Number
NCT01382134. The study was carried out according to
the Declaration of Helsinki. Sixty healthy volunteers were
recruited from August 2011 to June 2012 and informed
consents were obtained from all of them. All subjects were
over eighteen years old and had no known medical disease
nor pregnant. Smokers, regular alcohol users and those
with a known history of bleeding disorder were excluded.
Subjects were instructed not to take any medication or
herbal preparations that would affect haemostasis in the
preceding two weeks. They were also instructed not to have
red wine or chocolate intake 24 h before blood collection.
Subjects were randomized by computer into aspirin
group, taking low dose aspirin 100 mg daily (Cartia
100 mg. Glaxo Smith Kline, Sigma Pharmaceuticals Pty
Ltd, Dandenong, Australia) or placebo group, taking
placebo daily for a total of three days. Fifteen males and
fifteen females were assigned to the aspirin group, while
thirteen males and seventeen females to the placebo
group. On the fourth day, morning urine samples were
collected for detection of urine 11-dehydro thromboxane
B2 (11-dehydro thromboxane B2 EIA Kit Cat. no. 19501.
Cayman Chemical Company, Michigan, USA) to check
for response to aspirin. On the sixth day, subjects were
invited to our laboratory for venous blood sampling and
drug testing. After collection of baseline blood samples,
subjects were randomized to receive subcutaneous injec-
tion of either 0.9 % sodium chloride (placebo), desmo-
pressin 1.5 microgram or 5 microgram made up to 1 ml
solution (Octostim 15microgram/ml Desmopressin Acet-
ate. Ferring International Center SA, St Prex, Switzerland).
Blood samples were collected two hours later from the
contralateral arm for post-treatment analysis.
All blood sampling, drug administration and measure-
ments were performed by investigators who were blinded
to the randomization codes. The venous blood samples
were stored in citrated samples (BD Vacutainer 0.109 M,
3.2 % Citrate Tube Cat. no. 363047. BD Diagnostics,
Dubai, United Arab Emirates). The blood samples were
then divided into two groups and subjected to in-vitro
hypothermia (37 °C versus 32 °C) and haemodiution
(undiluted versus dilution with 20 % by volume of normal
saline). They were subjected to the following tests: (1)
PFA-100® closure times (PFA-100 Platelet Function
Analyzer. Dade Behring Inc, West Sacrameto, USA), using
collagen/adenosine diphosphate (ADP) and collagen/epi-
nephrine (EPI) cartridges as described previously [15]
(Dade PFA collagen/EPI Test Cartridge Cat. no. B4170-20;
Dade PFA collagen/ADP Test Cartridge Cat. no. B4170-
21; Both from Siemens Healthcare Diagnostic Products
GmbH, Marburg, Germany). They were incubated at 32
or 37 °C for 15 min before performing any PFA-100® mea-
surements; (2) full blood count (pocH-100i Automated
Hematology Analyzer. Sysmex Corporation, Kobe, Japan)
and plasma fibrinogen (CA-50 Automated Blood Coagula-
tion Analyzer. Sysmex Corporation, Kobe, Japan); (3)
plasma von Willebrand Factor (vWF) antigen (Imubind
vWF ELISA plate Cat. no. 828. American Diagnostica Inc,
Stamford, US).
Repeated measures analysis of variance (RANOVA) and
Chi-square tests were used in analysis of closure times
within each group. Inter-group comparisons were ana-
lyzed using Mann–Whitney U test (for 2 independent
groups) and Wilcoxon Signed-rank test (for 2 dependent
groups) due to violation of normal distribution. Post-hoc
comparisons were performed with paired t-test with
Bonferroni correction. Statistical analysis was performed
using SAS System for Windows Release 9.2, SAS Institute
Inc., Cary, NC, USA. A p value of <0.05 is considered sig-
nificant. Using a standard deviation of 16 % of the values
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of mean closure times obtained from other healthy volun-
teers at our centre, our study would have a power of 90 %
for detection of a 25 % change in PFA-100® closure times
with ten subjects in each group [16].
Results
A total of sixty subjects were recruited in the study and all
were included in data analysis (Fig. 1). One subject from
the placebo group reported mild facial swelling and stom-
ach discomfort later the day after having desmopressin
injection, which was self-limiting and no serious adverse
reactions were reported.
Levels of urinary 11 dehydro thromboxane B2 in aspirin-
taking subjects were significantly lower than that of pla-
cebo group (Fig. 2). Table 1 showed the baseline closure
time measurements of both aspirin and placebo groups.
The baseline EPICTs were significantly prolonged in as-
pirin group by 21.13 % (95 %Cl 2.34–39.74 %, p = 0.021)
when compared with the placebo group. Hypothermia
alone prolonged both ADPCT and EPICT by 17.63 %
(95 %Cl 13.5–20.85 %, p < 0.001) and 8.0 % (95 %Cl 6.38–
Fig. 1 Flow diagram of patient recruitment
Tsui et al. BMC Anesthesiology  (2015) 15:80 Page 3 of 7
10.04 %, p = 0.024) respectively when compared to nor-
mothermic values. The combination of aspirin and
hypothermia further prolonged EPICT by 19.9 % (95 %Cl
3.32–36.49 %, p = 0.013) when compared with hypothermia
alone, but ADPCT was not significantly prolonged.
The administration of desmopressin significantly re-
duced both ADPCT and EPICT of aspirin group at 37 °C
(Fig. 3). While there was significant reduction of ADPCT
at doses 1.5 microgram (p = 0.025) and 5 microgram
(p <0.001) when comparing to baseline values, an insig-
nificant reduction of EPICT was seen with 1.5 micro-
gram (p = 0.65) and significant reduction at 5 microgram
(p = 0.008).
At 32 °C under the influence of aspirin, desmopressin
produced a less pronounced effect on the closure times
(Fig. 4). With desmopressin 1.5 microgram, both ADPCT
and EPICT were not significantly different from their base-
line values at 37 °C. At a dose of 5 microgram, desmopres-
sin caused a mild but insignificant reduction of ADPCT
when compared to baseline values at 37 °C (p = 0.431),
while a significant reduction was only seen with EPICT
(p = 0.011). The dose response curves of desmopressin did
not seem to be temperature-dependent, as the slopes of










































11 dehydro thromboxane B2 amount in Day 4 urine sample
Fig. 2 Levels of 11-dehydro thromboxane B2 in aspirin group and
placebo group. ( ) represents aspirin group and ( ) represents
placebo group. p < 0.001
Table 1 Baseline closure times of aspirin and placebo groups at
37 °C
Aspirin group 37 °C Placebo group 37 °C p value
(n = 30) (n = 30)
ADPCT 120.7 ± 46.6 123.9 ± 42.5 0.728
EPICT 211.3 ± 68.9 174.6 ± 56.8 0.021+
Aspirin group 32 °C Placebo group 32 °C p value
(n = 30) (n = 30)
ADPCT 142.3 ± 58.2 145.7 ± 62.6 0.690
EPICT 226.1 ± 67.6 188.6 ± 52.5 0.013+
Values in mean ± SD
+Significant at the 0.05 level
ADPCT: Collagen/adenosine diphosphate closure time
EPICT: Collagen/adrenaline closure time
Fig. 3 Effects of desmopressin on PFA-100® closure times ADPCT (a)
and EPICT (b) of aspirin group at 37 °C. Bars represent control
(normal saline) ( ), desmopressin 1.5 microgram ( ) and 5
microgram ( ) respectively. * indicates p < 0.05. Error bars indicate
SD. ADPCT: Collagen/adenosine diphosphate closure time. EPICT:
Collagen/adrenaline closure time
Tsui et al. BMC Anesthesiology  (2015) 15:80 Page 4 of 7
The vWF antigen did not show a significant increase after
desmopressin 1.5 microgram and 5 microgram (Table 2).
Other parameters did not show any significant change, except
for haemoglobin level which showed a statistical significant
(p < 0.05) but probably not clinically significant difference.
While results from hypothermia group were presented
in this paper, those from haemodilution group shall be
presented in a separated report in the future.
Discussion
The design of this study was based on our previous studies
on evaluation of hypothermia-induced primary haemostasis
impairment and the effect of desmopressin on such im-
pairment [14, 17]. In this study, it was shown once again
the baseline ADPCT and EPICT were significantly pro-
longed in presence of hypothermia. The addition of as-
pirin further prolonged the EPICT, showing a synergistic
effect between hypothermia and aspirin on primary
haemostasis impairment. As it is not uncommon to see
patients taking aspirin peri-operatively, this may have clin-
ical implication on peri-operative blood loss where
hypothermia is difficult to avoid totally. In addition, it was
previously shown that an EPICT >188 s could predict in-
creased drain output in patients taking non-steroidal anti-
inflammatory drugs after total knee arthroplasty with a
sensitivity of 89 % [18]. EPICT prolongation in the presence
of hypothermia and aspirin could therefore potentially
predict an increase in peri-operative blood loss.
Fig. 4 Effects of desmopressin on PFA-100® closure times ADPCT (a)
and EPICT (b) of aspirin group at 32 °C. Bars represent control
(normal saline) ( ), desmopressin 1.5 microgram ( ) and 5
microgram ( ) respectively. * indicates p < 0.05. Error bars indicate






































































Fig. 5 Effect of different doses of desmopressin on PFA-100® on
ADP closure time (ADPCT (a)) at 32 °C (∎) and 37 °C (▽), as well as
adrenaline closure time (EPICT (b)) at 32 °C (●) and 37 °C (△)
respectively. * indicates p < 0.05. Error bars indicate SD
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In our previous studies, we have shown that low dose
subcutaneous desmopressin could improve hypothermia-
induced impairment in primary haemostasis [17]. It was
shown that the dosage required could be as low as 1.5
microgram, much lower than the standard dose of 15
microgram used in treating platelet dysfunction associated
with uraemia or cirrhosis. In this follow-up study, it was
shown that desmopressin at dosage of 1.5 microgram and
5 microgram could correct the ADPCT and EPICT to
close to baseline values under the influence of hypo-
thermia and aspirin. Such effect was milder at 32 °C when
compared to 37 °C measurements. In fact, there seemed
to be a trend for the 5 microgram dose to over-correct
closure times to below baseline values (Figs. 2 and 3).
Therefore we postulated that at dosage of 1.5 microgram
desmopressin might be sufficient to cause improvement in
hypothermia induced primary haemostasis impairment
under the influence of aspirin.
Being a point-of-care monitoring of coagulation status,
it has been suggested that the PFA-100® could be used
as a means to monitor the effectiveness of aspirin
therapy [19–22]. “Aspirin responders” and “aspirin non-
responders” could be identified using population based
cut-off values. In one particular study, Coakley et al.
showed that PFA-100® could be used to identify “aspirin
hyper-responders” peri-operatively [22]. This could allow
us to identify a small group of “aspirin hyper-responders”
who might be at risk of increased perioperative bleeding in
presence of hypothermia and have their aspirin therapy
evaluated before major operations. Indiscriminative cessa-
tion of aspirin therapy peri-operatively might unnecessarily
pose the patients to increased risk of thrombotic events.
PFA-100® could also be used as a screening tool for primary
haemostasis abnormalities before surgery [23]. Although it
is worth noting that studies so far had failed to show any
clinical benefit of using PFA-100® (such as prediction of
increased peri-operative blood loss) in peri-operative
situations [24, 25].
The thrombotic risk of desmopressin could be related
to its ability of causing prolonged von Willebrand factor
(vWF) release. Our data showed that at the doses used
in this study, there was no significant increase in vWF
release. This is in concordance with our previous studies
where low dose desmopressin corrects primary haemo-
stasis impairment without causing an increase in vWF
levels [17]. In an in vitro setting, the absence of endothe-
lial cells means that there will not be vWF release ac-
counting for the improvement in primary haemostasis.
These suggested that desmopressin has direct effect on
platelets itself, possibly via stimulated expression of ad-
hesion molecules such as glycoprotein Ib and p-selectin
[26–30]. Our studied dosages might allow safe and
effective use of desmopressin on improving primary
haemostasis impairment while minimizing the risk of
thrombotic complications.
There are several limitations of our study. Firstly, this
is an in vitro study based on healthy volunteers. Blood
samples were first collected then incubated to 32 °C and
37 °C respectively. The in vitro setting may not reveal in
vivo effects of desmopressin in hypothermic patients.
Previous studies on the effectiveness of desmopressin on
reduction of peri-operative blood loss had also shown
mixed results [31–33]. In addition, whether desmopres-
sin could improve haemostasis impairment due to other
causes (e.g., haemodilution, acidosis, noval anti-platelet
agents) remained elusive.
Conclusion
In conclusion, aspirin could have a synergistic effect
with hypothermia on primary haemostasis impairment.
Such impairment could be reversed by subcutaneous
low-dose desmopressin (1.5 microgram). This holds a
promising and safe way to improve primary haemostasis
impairment in aspirin taking patients undergoing major
operations, where hypothermia may be difficult to avoid.
Large scale clinical trials are warranted to further evalu-
ate the efficacy and safety of desmopressin on this as-
pect. In addition, the PFA-100® might have a role in
identifying “aspirin hyper-responders” who might be at
risk of increased surgical bleeding. This could allow se-
lective identification of high risk groups and have their
peri-operative anti-thrombotic therapy reviewed, without
Table 2 Aspirin group - concentrations of von Willebrand factor antigen (vWF:Ag), haemoglobin (Hb), fibrinogen (FIB) and platelet
count, in subjects receiving saline or desmopressin 1.5 and 5 μg subcutaneously
Saline Desmopressin 1.5 Desmopressin 5
(n = 10) (n = 10) (n = 10)
Baseline Post Baseline Post Baseline Post
von Willebrand factor antigen; mU.ml−1 1051.3 ± 320.9 978.8 ± 509.5 918.6 ± 346.0 1028.8 ± 384.2 1025.6 ± 430.1 1266.5 ± 589.7
Hb; g.dl−1 14.4 ± 1.4 14.3 ± 1.3 13.9 ± 1.1 13.5 ± 1.0+ 14.8 ± 1.4 13.9 ± 1.8+
Platelets; x 109 l−1 218.0 ± 65.9 232.8 ± 52.6 222.0 ± 54.0 228.2 ± 32.3 258.9 ± 36.6 259.6 ± 41.2
FIB; mg.dl−1 332.0 ± 72.1 342.0 ± 69.6 337.1 ± 105.9 368.5 ± 75.1 364.4 ± 47.8 355.1 ± 53.4
Values in mean ± SD
+p < 0.05 within group post-treatment compared with baseline (Wilcoxon Signed-rank test)
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risking the majority of thrombotic events with indiscri-
minative cessation of aspirin therapy.
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